Akero Therapeutics, Inc. (0K4.F)

34.60 -2.60 (-6.99%) At close: 08:00AM CEST

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://www.akerotx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 34

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Andrew Cheng M.D., Ph.D.	Pres, CEO & Director	882.76k	489.7k	1967
Dr. Jonathan M. Young J.D., Ph.D.	Co-Founder, Exec. VP, COO & Sec.	599.89k	376.91k	1970
Dr. Timothy Rolph	Co-Founder & Chief Scientific Officer	599.89k	N/A	1954
Mr. William R. White J.D.	Exec. VP, CFO, Treasurer & Head of Corp. Devel.	593.27k	1.75M	1974
Ms. Catriona Yale	Exec. VP & Chief Devel. Officer	562.39k	N/A	1972
Mr. Patrick Lamy	Sr. VP of Commercial Strategy	N/A	N/A	N/A
Mr. John J. Schembri	VP of Fin. & Controller	N/A	N/A	1962

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Akero Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.